|
|
|
Collegium Pharmaceutical inc (COLL) |
|
|
|
| |
Collegium Pharmaceutical Inc Income Statement Quarterly
COLL
|
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Sep 30 2024)
III. Quarter |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Sep 30 2023)
III. Quarter |
| Revenue From Contract With Customer Excluding Assessed Tax |
159.30 |
145.28 |
144.92 |
|
136.71 |
| Revenue From Contract With Customer Product And Service Extensible List |
- |
- |
- |
|
- |
| Other Revenue |
-0.51 |
-0.47 |
-0.47 |
|
-0.40 |
| Total Revenue |
158.79 |
144.81 |
144.46 |
4.27 |
136.31 |
| Cost of Revenues |
62.00 |
54.00 |
53.00 |
90.37 |
56.00 |
| Gross
Profit |
96.79 |
90.81 |
91.46 |
94.63 |
80.31 |
| Selling, Administration, Marketing |
61.96 |
43.34 |
41.98 |
32.94 |
35.30 |
| Depriciation & Amortization |
- |
- |
- |
- |
- |
| Research and Development Expense |
- |
- |
- |
- |
- |
| Restructuring Charges |
- |
- |
- |
- |
- |
| Other operatinig exp. /-income |
- |
- |
0.00 |
-180.73 |
- |
| Unusual Expense /-Income |
- |
- |
- |
- |
- |
| Total operating costs including COS |
123.96 |
97.34 |
94.98 |
-57.42 |
91.30 |
| Operating income/-loss
|
34.84 |
47.47 |
49.47 |
61.69 |
45.01 |
|
Other Deductions / - Income |
| Interest expense |
- |
- |
17.34 |
19.28 |
20.77 |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
- |
- |
17.34 |
19.28 |
20.77 |
| Extinguishment of Debt |
-4.15 |
-7.18 |
- |
-47.01 |
- |
| Investment Income, Net |
3.28 |
4.40 |
-4.49 |
- |
-4.54 |
| Foreign Currency Transaction (Gain) Loss |
- |
- |
- |
- |
- |
| Allowances, Health Care Trust Fund And Other |
- |
- |
- |
- |
- |
| Unexpected (Gain) Loss |
- |
- |
- |
- |
- |
| Other loss/ -income |
20.12 |
21.16 |
0.00 |
42.71 |
0.00 |
| Total costs & expenses |
143.21 |
115.71 |
107.83 |
-42.45 |
107.53 |
| Income /-loss before income taxes |
15.58 |
29.10 |
36.62 |
46.71 |
28.78 |
| Income taxes expenses/-benefit |
6.25 |
9.49 |
8.91 |
14.77 |
8.15 |
| Income after income taxes |
9.34 |
19.61 |
27.71 |
31.94 |
20.63 |
| Net income/-loss
of other equity |
- |
- |
- |
- |
- |
| Income/-loss
from cont. Ops. |
9.34 |
19.61 |
27.71 |
31.94 |
20.63 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
- |
- |
- |
- |
- |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
9.34 |
19.61 |
27.71 |
31.94 |
20.63 |
| Noncontrolling interests |
- |
- |
- |
- |
- |
| Prefered dividends |
- |
- |
- |
- |
- |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
9.34 |
19.61 |
27.71 |
31.94 |
20.63 |
| EBIT |
15.58 |
29.10 |
53.96 |
65.99 |
49.55 |
| EBITD |
16.53 |
30.05 |
54.88 |
66.94 |
50.39 |
| EBITDA |
58.54 |
66.17 |
91.18 |
66.94 |
88.83 |
| Per
Share (GAAP Quarterly, in $) |
(Sep 30 2024)
III. Quarter |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Sep 30 2023)
III. Quarter |
| Basic EPS (excl. extra
items) |
0.29 |
0.60 |
0.86 |
0.99 |
0.61 |
| Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Basic Net EPS |
0.29 |
0.60 |
0.86 |
0.99 |
0.61 |
| Basic shares outstanding (Mill.
of Units) |
32.26 |
32.43 |
32.33 |
32.28 |
33.74 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
0.27 |
0.52 |
0.71 |
0.58 |
0.53 |
| Diluted average shares (Mill.
of Units) |
40.16 |
40.38 |
41.44 |
37.33 |
42.06 |
| Dividend per share |
- |
- |
- |
- |
- |
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
